Biogen (BIIB) Stock Forecast & Price Target

$146.47 -0.92 (-0.62%)

(As of 12/20/2024 05:45 PM ET)

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 29 Analyst Ratings

Sell
0

Hold
16

Buy
13

Based on 29 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 29 analysts, 16 have given a hold rating, and 13 have given a buy rating for BIIB.

Consensus Price Target

$242.68
65.69% Upside

According to the 29 analysts' twelve-month price targets for Biogen, the average price target is $242.68. The highest price target for BIIB is $342.00, while the lowest price target for BIIB is $164.00. The average price target represents a forecasted upside of 65.69% from the current price of $146.47.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

BIIB Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	15 Buy rating(s)	17 Buy rating(s)	20 Buy rating(s)
Hold	16 Hold rating(s)	13 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$242.68	$257.20	$275.30	$319.67
Forecasted Upside	65.69% Upside	62.89% Upside	40.60% Upside	23.92% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here.

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.45	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	65.69% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	BMO Capital Markets 4 of 5 stars	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$230.00 ➝ $164.00	+11.27%
12/16/2024	Stifel Nicolaus 4 of 5 stars		Downgrade	Buy ➝ Hold	$175.00	+16.64%
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Neutral	$178.00	+13.77%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$250.00 ➝ $180.00	+14.08%
11/21/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$251.00 ➝ $207.00	+32.69%
11/18/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$270.00 ➝ $270.00	+68.76%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/15/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$294.00 ➝ $300.00	+81.94%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$190.00	+14.60%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$220.00 ➝ $210.00	+22.40%
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $180.00	+2.18%
10/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $255.00	+44.75%
10/31/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$300.00 ➝ $275.00	+56.24%
10/31/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+69.35%
10/31/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$285.00 ➝ $204.00	+12.60%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$292.00 ➝ $269.00	+45.47%
10/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$234.00 ➝ $202.00	+9.42%
9/23/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$210.00 ➝ $205.00	+4.17%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$292.00 ➝ $292.00	+46.34%
8/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$340.00 ➝ $302.00	+50.14%
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$240.00 ➝ $225.00	+9.76%
8/2/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Outperform ➝ Sector Outperform	$275.00 ➝ $244.00	+18.10%
7/12/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$335.00 ➝ $313.00	+32.18%
7/3/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/3/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$339.00 ➝ $342.00	+57.23%
2/20/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$310.00 ➝ $305.00	+39.35%
2/12/2024	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$290.00 ➝ $280.00	+14.82%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
5/11/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $350.00	+11.73%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$300.00 ➝ $315.00	+12.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:29 PM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. has a strong market presence in the biotechnology sector, focusing on therapies for neurological and neurodegenerative diseases, which are critical areas of medical need.
The company recently reported earnings per share (EPS) of $4.08, exceeding analysts' expectations of $3.77, indicating strong financial performance and effective management.
With a current stock price of $160.53, there is potential for growth, as analysts have set a price target of $178.00, suggesting a possible upside of 13.87% from the current level.
Biogen Inc. has a solid institutional backing, with 87.93% of its stock owned by hedge funds and other institutional investors, which often indicates confidence in the company's future prospects.
The company has a relatively low debt-to-equity ratio of 0.28, suggesting a strong balance sheet and lower financial risk, which can be attractive to investors looking for stability.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Biogen Inc. has experienced a decline in quarterly revenue, reporting a 2.5% decrease year-over-year, which may raise concerns about its growth trajectory.
The stock has a relatively low price-to-earnings (P/E) ratio of 14.53, which could indicate that the stock is undervalued, but it may also reflect market skepticism about future growth.
Recent downgrades from analysts, including a reduction in price targets by firms like Jefferies Financial Group, suggest a cautious outlook on the stock's performance.
Biogen Inc. has a beta of -0.08, indicating that its stock price is less volatile than the market, which may limit potential gains during bullish market conditions.
The company faces significant competition in the biotechnology field, which could impact its market share and profitability in the long run.

BIIB Forecast - Frequently Asked Questions

: According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $242.68, with a high forecast of $342.00 and a low forecast of $164.00.
: 29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 16 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
: According to analysts, Biogen's stock has a predicted upside of 65.69% based on their 12-month stock forecasts.
: Over the previous 90 days, Biogen's stock had 5 downgrades and 1 upgrade by analysts.
: Biogen has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Citigroup, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, UBS Group, Wedbush, and Wolfe Research in the past 90 days.
: Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:BIIB) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target